Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 12, 2005, Pages 1838-1842

  Byun, Kwan Soo ^a   Kwon, Oh Sang ^b   Kim, Ju Hyun ^b   Yim, Hyung Joon ^a   Chang, Yun Jung ^a   Kim, Jin Yong ^a   Yeon, Jong Eun ^a   Park, Jong Jae ^a   Kim, Jae Seon ^a   Bak, Young Tae ^a   Lee, Chang Hong ^a  

^a Korea University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Lamivudine; Relapse

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; DISEASE DURATION; FEMALE; HEPATITIS B; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VIRUS HEPATITIS; BLOOD; CHI SQUARE DISTRIBUTION; KOREA; LIVER FUNCTION TEST; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETREATMENT;

ADULT; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; KOREA; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETREATMENT; RISK FACTORS;

EID: 33644878638     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03952.x     Document Type: Article

References (17)

1. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998 339 : 61 8.
2. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999 341 : 1256 63.
3. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999 30 : 1082 7.
4. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003 37 : 748 55.
5. de Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on hepatitis B (13-14 September, 2002 Geneva, Switzerland). Consensus statement (long version). J. Hepatol. 2003 39 (Suppl. 1 S3 25.
6. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000 32 : 803 6.
7. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg seroconversion. J. Hepatol. 2003 39 : 614 19.
8. Kwon OS Byun KS Kim JH et al. High rate of early post-treatment relapse in chronic hepatitis B patients with HBeAg seroconversion after lamivudine treatment. J. Hepatol. 2001 34 (Suppl. 1 174.
9. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001 34 : 1225 41.
10. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J. Viral Hepat. 2002 9 : 208 12.
11. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003 38 : 1267 73.
12. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002 36 : 1425 30.
13. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002 122 : 1756 62.
14. Cho IH, Song JY, Kim DK et al. Prevalence of HBV genotypes in Korean patients with chronic hepatitis B. Korean J. Hepatol. 2001 7 : 381 6.
15. Lee CM, Ong GY, Lu SN et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J. Hepatol. 2002 37 : 669 74.
16. Lok AS, McMahon BJ. Chronic hepatitis B: Update recommendations. Hepatology 2004 39 : 857 61.
17. Liaw YF, Leung N, Guan R, Lau GK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003 18 : 239 45.